SB 355 Summary

• Prohibits pharmacy benefits managers from discriminating against 340B covered entities or specified pharmacies in payment terms, reimbursement methods, network participation requirements, or audit frequency based on their 340B status or dispensing of discounted drugs.

• Bars pharmacy benefits managers from refusing to contract with or terminating contracts with 340B entities, retaliating against them, or interfering with patients' choice to receive covered drugs from 340B covered entities or specified pharmacies.

• Requires drug manufacturers to comply with federal 340B pricing requirements when selling covered drugs to 340B covered entities in Connecticut and prohibits restrictions on dispensing locations, conditioning sales on third-party vendor enrollment, or charging above the federal ceiling price.

• Exempts the federal Medicare program and HUSKY Health program from these requirements, though contractors with these programs who have discretion to set drug payment rates remain subject to the restrictions.

• Becomes effective October 1, 2022, and directs the Insurance Commissioner to adopt implementing regulations.